Qiagen N.V. Stock News

High demand for COVID-19 test products and improving trends in the non-COVID portfolio drove QIAGEN's (QGEN) fourth-quarter revenues.

Qiagen N.V. (NYSE: QGEN ) clocked Q4 revenues of $582.39 million , +2% Y/Y, and well above the consensus of $461.30 million. At constant exchange rates (CER), Q4 revenues jumped 4% Y/Y, beating the outlook of a 9% CER decline provided by the company in November . Qiagen said that Q4 growth was driven by high demand for COVID-19 test products as well as … Full story available on Benzinga.com

Qiagen N.V.  QGEN clocked Q4 revenues of $582.39 million, +2% Y/Y, and well above the consensus of $461.30 million.

Qiagen Earnings, Revenue Beat in Q4

An 8% increase in sales of its non-COVID products in Q4 2021 compared to the prior-year period helped Qiagen beat both on the top and bottom line.

Diagnostics company Qiagen on Tuesday projected 2022 profit above market estimates, signaling that a rebound in its non-COVID businesses would offset a drop in coronavirus testing demand.

Qiagen press release (QGEN): Q4 Non-GAAP EPS of $0.74 beats by $0.14.Revenue of $582M (+1.9% Y/Y) beats by $46.53M.QIAGEN initiates 2022 outlook for at least $2.07 billion net…

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Axsome To Pay $312,500 To Settle Patent Infringement Litigation With Baudax Axsome Therapeutics, Inc.

Qiagen (NYSE:QGEN) is scheduled to announce Q4 earnings results on Tuesday, February 8th, after market close.The consensus EPS Estimate is $0.60 (-11.8% Y/Y) and the consensus

QIAGEN (QGEN) said its QuantiFERON tuberculosis ((TB)) Gold Plus, the fourth generation of the test, received approval in China and a new endorsement from the World Health

QuantiFERON-TB Gold Plus (QFT-Plus), the fourth generation of the modern gold standard for TB detection, receives Chinese NMPA approval as test for active tuberculosis detection World Health Organization (WHO) endorses QFT-Plus as alternative IGRA test for diagnosis of TB infection, recommends new QIAreach QFT for research use in epidemiological settings QIAGEN N.V. (NYSE: QGEN , Frankfurt Prime Standard: QIA)) today announced that its QuantiFERON tuberculosis (TB) testing solution has gained additional momentum with the approval of the fourth generation of this modern gold standard test in China and a new endorsement from the World Health Organization (WHO). Among the recent developments: China''s National Medical Products Administration (NMPA) has approved QuantiFERON-TB Gold Plus (QFT-Plus) for TB diagnosis, including active TB infections. This builds on the regulatory approvals for QFT-Plus for latent TB diagnosis in the U.S. and other countries around the world, including CE-IVD marking.

Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some bi

Growth-oriented investors may want to consider the following stocks, since they represent businesses with price-earnings ratios below 20 that recorded significant improvements in their trailing 12-mon

Investors continue to be optimistic about QIAGEN's (QGEN) progress with testing solutions and strategic collaborations.

Investors continue to be optimistic about QIAGEN's (QGEN) progress with testing solutions and strategic collaborations.